microdose glp 1 peptide GLP-1 Injections 💉 GLP-1: Macro-dosing vs Micro-dosing

Patients with severe kidney disease (eGFR below 2030) Patients with recurrent UTIs or fungal infections Type 1 diabetes patients (unless specifically prescribed) Pregnant women References: Protective Influence of SGLT-2 Inhibitors Against Heart Failure PMC 2024 Clinical Evidence for Cardiovascular & Kidney Benefits PMC SGLT2 Inhibitors: Antidiabetic and Cardioprotective Effects PMC Emerging Horizons: SGLT-2 Inhibitors Beyond Diabetes PMC DPP-4 inhibitors, sulfonylureas, TZDs So far we have covered the star players Metformin, GLP-1 agonists, and SGLT2 inhibitors

These trials revealed that empagliflozin-treated patients with left ventricular ejection fraction 40% experienced a lower risk of cardiovascular death or hospitalization for heart failure regardless of the presence or absence of diabetes [26, 27]

Day supply capped at 180 days

The imbalance of gut microbiota will reduce the production of SCFAs, weaken the ability to activate SCFAs receptors, and affect GLP-1 secretion, resulting in abnormal glucose metabolism and lipid metabolism (Ma et al., 2019)

If calcitonin testing is performed for clinical reasons and results are elevated, confirmation with repeat testing is advisable